Sugi Predict

Sugi Predict / Compounds / SCHEMBL6736839

SCHEMBL6736839

SCHEMBL6736839

CS(=O)(=O)c1cc(F)c(-c2nc(C(F)(F)F)[nH]c2-c2cc(F)ccc2F)cc1F

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPK14 Q16539 5/20 0.39
▸ BRAF P15056 4/20 0.35
▸ SLC9A1 P19634 1/20 0.35
▸ KIT P10721 1/20 0.35
▸ NR1H2 P55055 3/20 0.34
▸ NR1H3 Q13133 3/20 0.34
▸ ALOX5AP P20292 2/20 0.33
▸ FEN1 P39748 2/20 0.33
▸ ALOX5 P09917 1/20 0.33
▸ CCR2 P41597 1/20 0.33
▸ KDM4E B2RXH2 1/20 0.32
▸ MITF O75030 1/20 0.32
▸ ALDH1A1 P00352 1/20 0.32
▸ LMNA P02545 1/20 0.32
▸ STAT3 P40763 1/20 0.32
▸ STAT1 P42224 1/20 0.32
▸ RAB9A P51151 1/20 0.32
▸ SMN1; SMN2 Q16637 1/20 0.32
▸ NPSR1 Q6W5P4 1/20 0.32
▸ TLR9 Q9NR96 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6734677 0.88 BRAF (0.44) MAPK14BRAFALOX5KDM4EMITF
SCHEMBL6729205 0.88 PTGS2 (0.37) MAPK14BRAFNR1H2NR1H3ALOX5AP
SCHEMBL6735451 0.84 PTGS2 (0.38) MAPK14BRAFNR1H2NR1H3ALOX5AP
SCHEMBL6729506 0.84 MAPK14 (0.36) MAPK14BRAFNR1H2NR1H3ALOX5AP
SCHEMBL6729150 0.83 PTGS2 (0.42) BRAFNR1H2NR1H3ALOX5APFEN1
SCHEMBL6739929 0.83 ESR1 (0.48) MAPK14NR1H2NR1H3ALOX5ALDH1A1
SCHEMBL6735914 0.83 BRAF (0.38) MAPK14BRAFNR1H2NR1H3ALOX5AP
SCHEMBL6733585 0.83 PTGS2 (0.42) MAPK14NR1H2NR1H3ALOX5APFEN1
SCHEMBL6740267 0.83 PTGS2 (0.39) MAPK14BRAFNR1H2NR1H3ALOX5
SCHEMBL6736539 0.82 ALOX5AP (0.42) MAPK14BRAFNR1H2NR1H3ALOX5AP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6699884-B2 ANTIINFLAMMATORY CYCLOOXYGENASE INHIBITORS. PHARMACIA CORPORATION 2004-03-02 — — US claimed
US-20040138261-A1 Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation PHARMACIA CORPORATION 2004-07-15 — — US disclosed
US-6699884-B2 ANTIINFLAMMATORY CYCLOOXYGENASE INHIBITORS. PHARMACIA CORPORATION 2004-03-02 — — US disclosed
US-6673818-B2 TREATING CYCLOOXYGENASE-2 MEDIATED DISORDERS, SUCH AS ARTHRITIS, PAIN, FEVER AND CANCER PHARMACIA CORPORATION 2004-01-06 — — US disclosed
US-20030149078-A1 Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation PHARMACIA CORPORATION 2003-08-07 — — US disclosed
US-20030032657-A1 Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation PHARMACIA CORPORATION 2003-02-13 — — US disclosed
EP-1251126-A2 Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation Pharmacia Corporation (US) 2002-10-23 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040138261-A1 Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation FPR1, FPR2, FPR3 MAPK14 2311/4885BRAF 763/4885SLC9A1 3510/4885
US-20030149078-A1 Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation FPR1, FPR2, FPR3 MAPK14 2311/4885BRAF 763/4885SLC9A1 3510/4885
US-20030032657-A1 Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation FPR1, FPR2, FPR3 MAPK14 2311/4885BRAF 763/4885SLC9A1 3510/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.